Last reviewed · How we verify
Active Rheumatoid Arthritis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| tumor necrosis factor inhibitors (TNFi) | tumor-necrosis-factor-inhibitors-tnfi | Pfizer | biologic | tumor necrosis factor | ||
| TNF Inhibitor | tnf-inhibitor | Pfizer | Monoclonal Antibody | TNF-alpha |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 2 drugs in Active Rheumatoid Arthritis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Active Rheumatoid Arthritis:
- Active Rheumatoid Arthritis treatment updates — RSS
- Active Rheumatoid Arthritis treatment updates — Atom
- Active Rheumatoid Arthritis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Active Rheumatoid Arthritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/active-rheumatoid-arthritis. Accessed 2026-06-10.
Related
- Active Rheumatoid Arthritis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing